View in EDS HTML Full Text PDF Full Text

Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.

Saved in:
Bibliographic Details
Title: Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
Authors: Safyan RA; University of Washington School of Medicine, Seattle, WA, 98195, United States.; Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States., White RA; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, United States., Gonda TA; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, United States., Lee SM; Columbia University Mailman School of Public Health, New York, NY, 10032, United States., Han J; Columbia University Mailman School of Public Health, New York, NY, 10032, United States., Kuriakose N; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, United States.; Department of Medicine, James J. Peters Bronx VA Medical Center, Bronx, NY, 10468, United States., Yamamoto NK; Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States., Kugel S; Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States., Jamison JK; Weill Medical College, Cornell University, New York, NY, 10065, United States., Manji GA; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, United States., Schwartz GJ; Case Comprehensive Cancer Center, Cleveland, OH, 44106, United States., Oberstein PE; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, United States., Bates SE; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, United States.; Department of Medicine, James J. Peters Bronx VA Medical Center, Bronx, NY, 10468, United States.
Source: The oncologist [Oncologist] 2026 Mar 09; Vol. 31 (4).
Publication Type: Journal Article; Clinical Trial, Phase II
Journal Info: Publisher: Oxford University Press Country of Publication: England NLM ID: 9607837 Publication Model: Print Cited Medium: Internet ISSN: 1549-490X (Electronic) Linking ISSN: 10837159 NLM ISO Abbreviation: Oncologist Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 41844546
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Safyan+RA%22">Safyan RA</searchLink>; University of Washington School of Medicine, Seattle, WA, 98195, United States.; Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States.<br /><searchLink fieldCode="AU" term="%22White+RA%22">White RA</searchLink>; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, United States.<br /><searchLink fieldCode="AU" term="%22Gonda+TA%22">Gonda TA</searchLink>; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, United States.<br /><searchLink fieldCode="AU" term="%22Lee+SM%22">Lee SM</searchLink>; Columbia University Mailman School of Public Health, New York, NY, 10032, United States.<br /><searchLink fieldCode="AU" term="%22Han+J%22">Han J</searchLink>; Columbia University Mailman School of Public Health, New York, NY, 10032, United States.<br /><searchLink fieldCode="AU" term="%22Kuriakose+N%22">Kuriakose N</searchLink>; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, United States.; Department of Medicine, James J. Peters Bronx VA Medical Center, Bronx, NY, 10468, United States.<br /><searchLink fieldCode="AU" term="%22Yamamoto+NK%22">Yamamoto NK</searchLink>; Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States.<br /><searchLink fieldCode="AU" term="%22Kugel+S%22">Kugel S</searchLink>; Fred Hutchinson Cancer Center, Seattle, WA, 98109, United States.<br /><searchLink fieldCode="AU" term="%22Jamison+JK%22">Jamison JK</searchLink>; Weill Medical College, Cornell University, New York, NY, 10065, United States.<br /><searchLink fieldCode="AU" term="%22Manji+GA%22">Manji GA</searchLink>; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, United States.<br /><searchLink fieldCode="AU" term="%22Schwartz+GJ%22">Schwartz GJ</searchLink>; Case Comprehensive Cancer Center, Cleveland, OH, 44106, United States.<br /><searchLink fieldCode="AU" term="%22Oberstein+PE%22">Oberstein PE</searchLink>; Laura and Isaac Perlmutter Cancer Center, NYU Langone Health, New York, NY, 10016, United States.<br /><searchLink fieldCode="AU" term="%22Bates+SE%22">Bates SE</searchLink>; Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, NY, 10032, United States.; Department of Medicine, James J. Peters Bronx VA Medical Center, Bronx, NY, 10468, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%229607837%22">The oncologist</searchLink> [Oncologist] 2026 Mar 09; Vol. 31 (4).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Oxford+University+Press%22">Oxford University Press </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9607837 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1549-490X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2210837159%22">10837159 </searchLink><i>NLM ISO Abbreviation: </i>Oncologist <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=41844546
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1093/oncolo/oyag091
    Languages:
      – Code: eng
        Text: English
    Titles:
      – TitleFull: Phase 2 study of azacitidine plus pembrolizumab as second-line treatment in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Safyan RA
      – PersonEntity:
          Name:
            NameFull: White RA
      – PersonEntity:
          Name:
            NameFull: Gonda TA
      – PersonEntity:
          Name:
            NameFull: Lee SM
      – PersonEntity:
          Name:
            NameFull: Han J
      – PersonEntity:
          Name:
            NameFull: Kuriakose N
      – PersonEntity:
          Name:
            NameFull: Yamamoto NK
      – PersonEntity:
          Name:
            NameFull: Kugel S
      – PersonEntity:
          Name:
            NameFull: Jamison JK
      – PersonEntity:
          Name:
            NameFull: Manji GA
      – PersonEntity:
          Name:
            NameFull: Schwartz GJ
      – PersonEntity:
          Name:
            NameFull: Oberstein PE
      – PersonEntity:
          Name:
            NameFull: Bates SE
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 09
              M: 03
              Text: 2026 Mar 09
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1549-490X
          Numbering:
            – Type: volume
              Value: 31
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: The oncologist
              Type: main
ResultId 1